Shots:

• The P-III ILLUMINATE-A Study involves assessing Lumasiran vs PBO in 39 patients with age 6 or older in a ratio (2:1) for PH1
• The study met its 1EPs demonstrated a 53.5% reduction in urinary oxalate excretion from baseline to 6 mos. i.e. change in 24 hrs. The 2EPs showed 84% of patients achieved normal or near-normal levels of urinary oxalate- include additional measures of Oxlumo- was safe and tolerable- with no serious or severe AEs
• Lumasiran is an RNAi therapeutic targeting HAO1 for the treatment of PH1 to lower urinary oxalate levels in pediatric and adult patients

  Ref: BusinessWire | Image: Alnylam